Submissions from 2008
Sales leaders as senior level management: Application of upper echelon theory for high growth companies, M. Rodriguez
Sales leaders as senior level managers: A conceptual framework for examining upper echelon theory, M. Rodriguez
Submissions from 2007
Hazards for pain severity and pain interference with daily living, with exploration of BPI cutpoints, among women with metastatic breast cancer, L. D. Castel, A. P. Abernathy, Y. Li, V. DePuy, B. R. Saville, and K. E. Hartmann
Risk factors for pain severity and interference over a year among women with metastatic breast cancer, L. D. Castel, A. P. Abernethy, Y. Li, V. DePuy, and K. E. Hartmann
Disparities in pain outcomes among women with metastatic breast cancer, L. D. Castel, B. R. Saville, V. DePuy, P. A. Godley, K. E. Hartmann, and A. P. Abernathy
Pain severity outcomes over one year among women with metastatic breast cancer: A hazards analysis of interval-censored data, L. D. Castel, B. R. Saville, V. DePuy, K. E. Hartmann, and A. P. Abernethy
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer, V. DePuy, K. J. Anstrom, L. D. Castel, K. A. Schulman, K. P. Weinfurt, and F. Saad
Submissions from 2006
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer, K. P. Weinfurt, K. J. Anstrom, L. D. Castel, K. A. Schulman, and F. Saad
Submissions from 2005
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer, K. P. Weinfurt, Y. Li, L. D. Castel, F. Saad, J. W. Timbie, G. A. Glendenning, and K. A. Schulman
Submissions from 2004
An exploration of the health stock risk adjustment model in advanced cancer patients, D. J. Gaskin, K. P. Weinfurt, L. D. Castel, V. DePuy, Y. Li, A. Balshem, A. Benson, C. B. Burnett, S. Corbett, J. Marshall, E. Slater, D. Sulmasy, D. Van Echo, N. J. Meropol, and K. A. Schulman
Health-related quality of life among breast cancer patients receiving zoledronic acid or pamidronate disodium for metastatic bone lesions, K. P. Weinfurt, L. D. Castel, Y. Li, J. W. Timbie, G. A. Glendenning, and K. A. Schulman
Understanding of an aggregate probability statement by patients who are offered participation in phase I clinical trials, K. P. Weinfurt, V. DePuy, L. D. Castel, D. P. Sulmasy, K. A. Schulman, and N. J. Meropol
Submissions from 2003
Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for un-compensated care, L. D. Castel, J. W. Timbie, V. Sendersky, L. H. Curtis, K. A. Feather, and K. A. Schulman
Perceptions of patients and providers regarding phase I cancer clinical trials: Implications for physician-patient communication, N. J. Meropol, K. P. Weinfurt, C. B. Burnett, A. Balshem, A. Benson, L. D. Castel, S. Corbett, M. Deifenbach, D. J. Gaskin, Y. Li, S. Manne, J. Marshall, E. Slater, D. Sulmasy, J. Rowland, D. Van Echo, S. Washington, and K. Schulman
The correlation between patient characteristics and expectations of benefit from phase I clinical trials, K. P. Weinfurt, L. D. Castel, Y. Li, D. P. Sulmasy, A. Balshem, A. Benson, C. B. Burnett, D. J. Gaskin, J. Marshall, E. Slater, D. Van Echo, K. A. Schulman, and N. J. Meropol
Submissions from 2002
The impact of welfare reform on hospital expenditures for uncompensated care, L. D. Castel, L. H. Curtis, J. W. Timbie, V. Sendersky, K. A. Feather, and K. A. Schulman
Use of the EuroQoL Visual Analogue Scale in assessing longitudinal changes in quality of life in cancer patients: A comparison with subscales of the Medical Outcomes Survey Short Form-36, L. D. Castel, S. Reed, K. Weinfurt, Y. Li, A. W. Law, N. Meropol, and K. A. Schulman
Submissions from 2001
A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease, L. D. Castel, K. Bajwa, J. P. Markle, J. W. Timbie, C. Zacker, and K. A. Schulman
Zoledronic acid versus pamidronate as palliative therapy in cancer patients: A Canadian time and motion analysis, G. Dranitsaris, L. D. Castel, J. F. Baladi, and K. Schulman
Submissions from 2000
A micro-costing analysis of pamidronate/zoledronic acid administration, K. Bajwa, L. D. Castel, J. Markle, C. Zacker, and K. Schulman
